Galena acquires swedish anti breakthrough cancer pain product (BTcP) Abstral
Galen has strengthens its product base by acquiring swedish breakthrough cancer pain product (BTcP) Abstral from Orexo – a listed swedish pharma company partly owned by Danish Diabates-giant Novo.
http://finance.yahoo.com/news/galena-biopharma-acquires-abstral-r-070000289.html
Ongoing debate
- James Rolitson on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Thomas Goldberg on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Spekulant.dk on dashboard
- Muldyr on dashboard
- kasperlindvig on dashboard

